Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) released select unaudited preliminary results for Q4 and full year 2025 and introduced full‑year 2026 guidance on Jan 12, 2026.

Preliminary revenue: Q4 2025 $207M–$209M; full year 2025 $822M–$824M. 2026 guidance: Revenue $860M–$880M, Adjusted Gross Margin 68%–69%, and Adjusted EBITDA $37M–$49M. The company will publish final audited results in February 2026 and host a webcast on Jan 14, 2026 at 5:15 pm PT.

Positive

• 2026 revenue guidance of $860M–$880M
• Midpoint revenue ~6% above 2025 midpoint
• Adjusted Gross Margin guidance of 68%–69%
• Adjusted EBITDA midpoint up ~43% vs prior midpoint

Negative

• Q4 and full‑year 2025 results are preliminary and unaudited
• Company cannot provide GAAP reconciliation for forward‑looking non‑GAAP metrics
• Adjusted measures include one‑time items that affect comparability

News Market Reaction

-0.15%

11 alerts

-0.15% News Effect

+3.6% Peak in 11 min

-$1M Valuation Impact

$666M Market Cap

0.2x Rel. Volume

On the day this news was published, MYGN declined 0.15%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.6% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $666M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Q4 2025 revenue (prelim): $207–$209 million Full-year 2025 revenue (prelim): $822–$824 million 2026 revenue guidance: $860–$880 million +5 more

8 metrics

Q4 2025 revenue (prelim) $207–$209 million Preliminary total revenue range for Q4 2025

Full-year 2025 revenue (prelim) $822–$824 million Preliminary total revenue range for full year 2025

2026 revenue guidance $860–$880 million Full-year 2026 revenue guidance range

2026 adjusted gross margin 68%–69% Full-year 2026 adjusted gross margin guidance

2026 adjusted EBITDA $37–$49 million Full-year 2026 adjusted EBITDA guidance range

JPM presentation time Jan 14, 2026 at 5:15 pm PT / 8:15 pm ET Investor webcast linked to preliminary results

Conference edition 44th Annual J.P. Morgan Healthcare Conference Event where results and guidance will be presented

Currency assumption date January 12, 2026 Date of FX rates assumed in 2026 guidance

Market Reality Check

Price: $5.92 Vol: Volume 844,946 is slightl...

normal vol

$5.92 Last Close

Volume Volume 844,946 is slightly below the 20-day average of 919,904, indicating no unusual trading ahead of the announcement. normal

Technical Shares at $6.58 are trading modestly above the 200-day MA of $6.43, after a large decline from the $15.47 52-week high.

Peers on Argus

MYGN’s modest pre-news gain of 0.3% comes amid mixed peer moves: FLGT up 0.32%, ...

MYGN’s modest pre-news gain of 0.3% comes amid mixed peer moves: FLGT up 0.32%, NEO up 2.73%, while CDNA and CSTL are down and PSNL is down 5.04%. This points to stock-specific focus rather than a uniform diagnostics rally.

Common Catalyst Several diagnostics peers, including NEO and CDNA, also released preliminary Q4 and full-year 2025 results, consistent with earnings/J.P. Morgan conference season.

Historical Context

5 past events · Latest: Jan 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Conference appearance	Neutral	+0.0%	Announcement of presentation slot at the J.P. Morgan Healthcare Conference.
Dec 09	Scientific data	Positive	+4.0%	Multiple SABCS abstracts highlighting MRD test data and expanded MyRisk panel.
Nov 25	AI collaboration	Positive	-3.9%	Launch of integrated AI and genetic risk platform for breast health.
Nov 11	Investor conferences	Positive	+3.1%	Participation in Wolfe Research and Piper Sandler healthcare investor conferences.
Nov 10	Product expansion	Positive	+2.9%	Expansion of MyRisk hereditary cancer test to 63 guideline-referenced genes.

Pattern Detected

Recent news flow shows mostly positive or neutral announcements with price reactions generally aligning to tone, except for a negative reaction to the AI breast health collaboration.

Recent Company History

Over the last few months, Myriad’s news has centered on clinical data, product expansion, and investor outreach. In Nov 2025, it expanded the MyRisk test to 63 genes and reported multiple conference participations with modestly positive price reactions. Scientific updates at SABCS in Dec 2025 also saw a positive move. The only notable divergence was a -3.92% reaction to the AI breast health collaboration in Nov 2025. Today’s preliminary 2025 figures and 2026 guidance fit into this cadence of frequent updates around key conferences.

Market Pulse Summary

This announcement provides preliminary Q4 and full-year 2025 revenue ranges of $207–$209 million and...

Analysis

This announcement provides preliminary Q4 and full-year 2025 revenue ranges of $207–$209 million and $822–$824 million, alongside 2026 guidance for revenue of $860–$880 million, adjusted gross margin of 68%–69%, and adjusted EBITDA of $37–$49 million. Compared with prior earnings updates that revised 2025 expectations, this continues a pattern of detailed outlook communication. Investors may watch how final audited results and execution versus 2026 targets evolve.

Key Terms

adjusted gross margin, adjusted EBITDA, GAAP, non-GAAP, +4 more

8 terms

adjusted gross margin financial

"Adjusted Gross Margin ** | 68% - 69% | This range incorporates the anticipated impact..."

Adjusted gross margin is a measure of how much profit a company makes from its sales after accounting for certain expenses or one-time costs, but before deducting other operating expenses. It helps investors see the company's core profitability more clearly by removing factors that might distort the usual profit picture, similar to a runner measuring their speed without considering obstacles or weather. This metric provides a clearer view of the company's ongoing financial health.

adjusted EBITDA financial

"Adjusted EBITDA*** | $37 - $49 | The mid-point of the adjusted EBITDA range..."

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

GAAP financial

"prepared in accordance with generally accepted accounting principles in the United States (GAAP)"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

non-GAAP financial

"forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance"

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

stock-based compensation financial

"For example, stock-based compensation may fluctuate based on the timing of employee stock transactions"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

amortization of intangible assets financial

"such as amortization of intangible assets and share-based compensation expense"

Amortization of intangible assets is the accounting practice of spreading the purchase cost of non-physical items—like patents, trademarks, or customer lists—over their expected useful life. Investors care because this non-cash charge reduces reported profits and book value over time, affecting earnings trends and valuation, even though it does not immediately change the company’s cash; think of it as paying off a large one-time purchase in small, regular amounts on the books.

impairment of long-lived assets financial

"such as amortization of intangible assets, depreciation, impairment of long-lived assets, and share-based compensation expense"

An impairment of long-lived assets occurs when a company concludes that a physical or intangible asset—like a building, equipment, or a patent—is worth less than its recorded value on the books, so the company writes down that asset to its recoverable amount. For investors this matters because such write-downs reduce reported profits and company net worth, signaling potential problems with future cash flow or that management overpaid for assets; think of it like recognizing that a car you bought has lost more value than you expected.

forward-looking statements regulatory

"These projections are forward-looking statements and are subject to the risks summarized in the safe harbor statement"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. Not financial advice.

SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance.

These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad.com on Wednesday, January 14, 2026 at 5:15 pm PT (8:15 pm ET) in connection with the company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference.

Select Preliminary Fourth Quarter and Full Year 2025 Financial Results 
The company expects the following: 

• Fourth quarter of 2025 total revenues to be between $207 million and $209 million.
• Full year 2025 total revenues to be between $822 million to $824 million.
  
  

The company plans to release its actual financial results for the fourth quarter and full year 2025 during its earnings call to be held in February 2026.

The select financial results for the quarter and full year ended December 31, 2025 set forth in this press release are preliminary and subject to Myriad Genetics’ normal quarter and year-end accounting procedures and external audit by the company’s independent registered public accounting firm. As a result, these select preliminary, unaudited financial results may change in connection with the finalization of the company’s year-end closing and reporting processes and financial statements for the quarter and full year ended December 31, 2025 and may not represent the actual financial results for the quarter and full year ended December 31, 2025. In addition, these select preliminary, unaudited financial results are not a comprehensive statement of the company’s financial results for the year ended December 31, 2025, should not be viewed as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP), and are not necessarily indicative of the company's results for any future period. 

2026 Financial Guidance
Myriad Genetics does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, strategic realignment, certain litigation charges and loss contingencies, costs related to acquisitions/divestitures and the related amortization, impairment and related charges, depreciation, equity compensation, tax benefits and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the company's stock price. Any associated estimate of these items and their impact on GAAP performance could vary materially. 

The company introduces the full year 2026 financial guidance in the table below.*

(in millions, except percentages)			Guidance	Comments
Revenue			$860 - $880	The mid-point of the 2026 revenue guidance range reflects an increase of approximately 6% compared to the mid-point of the preliminary 2025 revenue range.
Adjusted Gross Margin **			68% - 69%	This range incorporates the anticipated impact from new product launches.
Adjusted EBITDA***			$37 - $49	The mid-point of the adjusted EBITDA range is expected to grow approximately 43% over the mid-point of the previous full year 2025 guidance range.
*	Assumes currency rates as of January 12, 2026.
**	Adjusted Gross Margin is defined as Gross Margin plus non-cash cost of sales, such as amortization of intangible assets and share-based compensation expense, and non-recurring one-time expenses.
***	Adjusted EBITDA is defined as Net Income (loss) plus income tax expense (benefit), total other income (expense), non-cash operating expenses, such as amortization of intangible assets, depreciation, impairment of long-lived assets, and share-based compensation expense, and one-time expenses such as expenses from strategic realignment, legal settlements, and divestitures and acquisitions.

These projections are forward-looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release. 

About Myriad Genetics  
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Statement regarding use of non-GAAP financial measures
In this press release, the company’s 2026 financial guidance is provided in accordance with GAAP and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the company’s business. The company does not forecast GAAP gross margin or GAAP EBITDA because it cannot predict certain elements that are included in reported GAAP results. Please see above under "2026 Financial Guidance" for a full explanation.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, if available, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the company’s fourth quarter and full year 2025 preliminary revenues and the company’s full year 2026 financial guidance. These “forward-looking statements” are management’s present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated.

These risks include, but are not limited to: the risk that sales and profit margins of the company’s existing tests may decline; the risk that the company may not be able to operate its business on a profitable basis; risks related to changes in the company's financial results from the preliminary results reported in this press release resulting from the finalization of the company's financial statements for the fourth quarter and full year 2025 and the audit thereof; risks related to the company’s ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable; risks related to recent changes in the company's senior management team and the successful implementation of the company's strategic plan; risks related to changes in governmental or private insurers’ coverage and reimbursement levels for the company’s tests or the company’s ability to obtain reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests; the risk that the company may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all; the risk that the company is not able to secure additional financing to fund its business, if needed, in a timely manner or on favorable terms, if it all; the risk that the company may not successfully develop new markets or channels for its tests; the risk that licenses to the technology underlying the company’s tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating the company’s laboratory testing facilities; risks related to public concern over genetic testing in general or the company’s tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the company’s ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; risks related to the company’s ability to successfully integrate and derive benefits from any technologies or businesses that it licenses, acquires or develops; risks related to the company’s projections or estimates about the potential market opportunity for the company’s current and future products; the risk that the company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the company’s tests; the risk of patent-infringement claims or challenges to the validity of the company’s patents; risks related to changes in intellectual property laws covering the company’s tests, or patents or enforcement, in the United States and foreign countries; risks related to security breaches, loss of data and other disruptions, including from cyberattacks and other cybersecurity incidents; risks of new, changing and competitive technologies in the United States and internationally and that the company may not be able to keep pace with the rapid technology changes in its industry, or properly leverage new technologies to achieve or sustain competitive advantages in its products; the risk that the company may be unable to comply with financial or operating covenants under the company’s credit or lending agreements; the risk that the company may not be able to maintain effective disclosure controls and procedures and internal control over financial reporting; risks related to current and future investigations, claims or lawsuits, including derivative claims, product or professional liability claims, and risks related to the amount of the company's insurance coverage limits and scope of insurance coverage with respect thereto; and other factors discussed under the heading “Risk Factors” contained in Part I, Item 1A of the company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. The company is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Investor Contact  
Matt Scalo  
(801) 584-3532  
IR@myriad.com  
  
Media Contact  
Kate Schraml 
(224) 875-4493 
PR@myriad.com   

FAQ

What preliminary revenue did Myriad Genetics (MYGN) report for Q4 2025?

Myriad provided a preliminary Q4 2025 revenue range of $207M–$209M.

What is Myriad Genetics' full year 2026 revenue guidance (MYGN)?

The company guided full year 2026 revenue of $860M–$880M.

How does Myriad (MYGN) say 2026 revenue compares to 2025?

Myriad states the 2026 midpoint is approximately 6% higher than the 2025 midpoint.

What 2026 profitability metrics did Myriad (MYGN) provide?

Guidance includes Adjusted Gross Margin 68%–69% and Adjusted EBITDA $37M–$49M.

When will Myriad (MYGN) release final audited 2025 results?

The company said it will release actual fourth quarter and full year 2025 results during its February 2026 earnings call.

When is Myriad's investor webcast discussing these results?

A live webcast is scheduled for Jan 14, 2026 at 5:15 pm PT (8:15 pm ET).